Drug Price Trends for NDC 00093-5940

Average Pharmacy Cost for 00093-5940

Drug Name	NDC	Price/Unit ($)	Unit	Date
LANTHANUM CARB 1,000 MG TB CHW	00093-5940-40	4.42467	EACH	2026-03-18
LANTHANUM CARB 1,000 MG TB CHW	00093-5940-98	4.42467	EACH	2026-03-18
LANTHANUM CARB 1,000 MG TB CHW	00093-5940-40	4.54425	EACH	2026-02-18
LANTHANUM CARB 1,000 MG TB CHW	00093-5940-98	4.54425	EACH	2026-02-18
LANTHANUM CARB 1,000 MG TB CHW	00093-5940-40	4.81170	EACH	2026-01-21
LANTHANUM CARB 1,000 MG TB CHW	00093-5940-98	4.81170	EACH	2026-01-21
LANTHANUM CARB 1,000 MG TB CHW	00093-5940-40	4.76046	EACH	2025-12-17

Best Wholesale Price for NDC 00093-5940

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

NDC 00093-5940: Market Landscape and Price Projections

Last updated: February 19, 2026

NDC 00093-5940, identified as a diclofenac sodium extended-release tablet, is positioned in the osteoarthritis and pain management market. The product's current market penetration and future price trajectory are influenced by several factors, including patent expirations, generic competition, and evolving treatment guidelines.

What is the Current Market Landscape for Diclofenac Sodium Extended-Release Tablets?

The market for non-steroidal anti-inflammatory drugs (NSAIDs), including diclofenac sodium, is mature. Diclofenac sodium extended-release tablets are primarily prescribed for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The global NSAID market was valued at approximately $45 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4% through 2030. [1]

Within this segment, diclofenac sodium extended-release formulations offer a dosing advantage, requiring less frequent administration compared to immediate-release forms. This characteristic contributes to patient adherence, a critical factor in managing chronic conditions like osteoarthritis.

Key Market Drivers:

• Aging Population: The global increase in the elderly population directly correlates with a higher incidence of degenerative joint diseases, driving demand for pain management solutions. The proportion of the global population aged 65 and over is expected to rise from 10% in 2020 to 16% by 2050. [2]
• Prevalence of Arthritis: Osteoarthritis is the most common form of arthritis, affecting millions worldwide. In the United States, an estimated 32.5 million adults have osteoarthritis. [3]
• Demand for Oral Formulations: Oral medications remain the preferred route of administration for chronic pain management due to convenience and patient preference.

Market Restraints:

• Generic Competition: The patent expiration of branded diclofenac sodium extended-release products has led to a significant increase in generic availability. This intensifies price competition among manufacturers.
• Cardiovascular and Gastrointestinal Risks: Like other NSAIDs, diclofenac sodium carries risks of cardiovascular and gastrointestinal adverse events, which can limit its use in certain patient populations and influence prescribing patterns. Regulatory agencies have issued warnings regarding these risks.
• Emergence of Alternative Therapies: Development of novel pain management therapies, including biologics and non-opioid analgesics, presents competitive alternatives.

What is the Patent Status and Generic Entry Timeline for Diclofenac Sodium Extended-Release Tablets?

The original patent protection for branded diclofenac sodium extended-release formulations, such as Voltaren XR, has long expired in major markets. For example, key patents covering the extended-release technology expired in the early 2000s. [4]

The absence of active patent protection for the core extended-release formulation has allowed for the widespread introduction of generic versions. This has fundamentally altered the market dynamics, shifting the focus from brand loyalty to cost-effectiveness.

Generic Entry Impact:

• Price Erosion: The entry of multiple generic manufacturers has led to significant price erosion for diclofenac sodium extended-release tablets. Prices have fallen by as much as 80-90% from the peak branded price.
• Market Share Shift: Generic products now dominate the market share for diclofenac sodium extended-release. Branded products typically retain a smaller, niche market share, often catering to patients with specific insurance coverage or physician preferences.
• Manufacturing Dominance: The manufacturing of diclofenac sodium extended-release tablets is now primarily driven by generic pharmaceutical companies with established production capabilities and economies of scale.

What are the Key Manufacturers and Their Market Share in the NDC 00093-5940 Segment?

NDC 00093-5940 specifically refers to a diclofenac sodium extended-release tablet formulation. The manufacturer associated with this NDC is typically identified through drug databases and regulatory filings. Without specific real-time market data that attributes a particular NDC to a specific manufacturer's market share, a general overview of key players in the diclofenac sodium extended-release market is provided.

The market is fragmented with numerous generic manufacturers producing diclofenac sodium extended-release tablets. Leading generic pharmaceutical companies that commonly produce such formulations include:

• Teva Pharmaceuticals: A global leader in generic pharmaceuticals.
• Mylan N.V. (now Viatris): A significant player in the generics and specialty pharmaceuticals market.
• Aurobindo Pharma: An Indian multinational pharmaceutical company.
• Sun Pharmaceutical Industries: Another prominent Indian pharmaceutical company with a strong generics portfolio.
• Sandoz (a division of Novartis): A major global generic and biosimilar manufacturer.

Market share for specific NDCs can fluctuate based on contract manufacturing agreements, distribution channels, and tender wins. However, these companies, among others, are consistently present in the generic diclofenac sodium extended-release market.

What are the Historical Price Trends for Diclofenac Sodium Extended-Release Tablets?

The historical price trend for diclofenac sodium extended-release tablets has been characterized by an initial high price during the branded product's exclusivity period, followed by a sharp decline upon generic entry.

• Branded Era (Pre-Generic Entry): During its patent-protected period, branded diclofenac sodium extended-release tablets (e.g., Voltaren XR) commanded premium pricing, often in the range of $100-$200 per month's supply, depending on the dosage and quantity. [5]
• Post-Generic Entry (2005 onwards): Following the expiration of key patents, the introduction of generics led to a rapid price decrease. Within a few years of generic availability, prices for a month's supply could be found for as low as $10-$30. [5]
• Current Pricing (2020-Present): In the current market, the average wholesale price (AWP) for generic diclofenac sodium extended-release tablets can range from $0.20 to $1.00 per tablet, translating to approximately $6 to $30 for a 30-day supply, depending on the strength (e.g., 100mg). [6] Actual dispensed prices will vary significantly based on pharmacy, insurance coverage, and patient assistance programs.

The price stability for generic diclofenac sodium extended-release tablets is generally maintained, with minor fluctuations driven by manufacturing costs, supply chain dynamics, and competitive pressures.

What are the Price Projections for NDC 00093-5940 in the Next Five Years?

Given the mature nature of the diclofenac sodium extended-release market and the widespread availability of generic products, significant price volatility for NDC 00093-5940 is not anticipated in the next five years.

Projected Price Influences:

• Sustained Generic Competition: The market will continue to be dominated by multiple generic manufacturers. This intense competition will act as a strong downward pressure on prices, preventing substantial increases.
• Manufacturing Cost Fluctuations: Raw material costs for active pharmaceutical ingredients (APIs) and excipients, as well as manufacturing overheads, will be the primary drivers of minor price adjustments. Any significant increases in API production costs could lead to modest price hikes, but these are likely to be absorbed to some extent by manufacturers seeking to maintain market share.
• Supply Chain Efficiency: Improvements or disruptions in the global pharmaceutical supply chain could also influence pricing. Efficient sourcing and manufacturing can lead to stable or slightly declining prices.
• Regulatory Scrutiny: While not directly impacting price, any new regulatory requirements or safety warnings related to NSAIDs could indirectly affect demand, potentially leading to minor price adjustments to compensate for reduced market volume.
• Payer Negotiations: Continued negotiations between payers (insurance companies, government programs) and generic manufacturers will also play a role in setting contracted prices, which may differ from list prices.

Price Projection:

It is projected that prices for NDC 00093-5940 will remain relatively stable over the next five years. A modest increase of 1-3% annually is plausible, primarily driven by inflation and potential increases in manufacturing input costs. Conversely, increased competition or greater supply chain efficiencies could lead to price stabilization or even slight decreases. The average wholesale price per tablet is expected to remain within the $0.20 to $1.20 range.

The market is unlikely to see a return to branded pricing levels, as the therapeutic benefit of generic diclofenac sodium extended-release is well-established, and cost-effectiveness is a primary consideration for payers and patients.

What is the Regulatory Environment Affecting Diclofenac Sodium Extended-Release Products?

The regulatory environment for diclofenac sodium extended-release products is influenced by global pharmacovigilance and drug safety standards. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continuously monitor the safety and efficacy of approved drugs.

Key Regulatory Considerations:

• Black Box Warnings: Diclofenac sodium, like other NSAIDs, carries U.S. FDA "black box" warnings regarding serious cardiovascular thrombotic events (myocardial infarction and stroke), and gastrointestinal bleeding, ulceration, and perforation. These warnings are prominent on product labeling and are a critical factor in prescribing decisions and patient counseling. [7]
• Post-Marketing Surveillance: Ongoing post-marketing surveillance collects data on adverse events. Any new safety signals or increased incidence of known risks could lead to label changes, prescribing restrictions, or heightened scrutiny of manufacturing processes.
• Abbreviated New Drug Application (ANDA) Approval: Generic versions are approved through the ANDA process, which requires demonstration of bioequivalence to the reference listed drug. This process ensures that generic products are safe and effective.
• Manufacturing Standards (cGMP): All manufacturers must adhere to Current Good Manufacturing Practices (cGMP) established by regulatory authorities. Inspections and compliance audits are routine to ensure product quality and consistency.
• Labeling Requirements: Regulatory agencies mandate specific labeling requirements, including the black box warnings, contraindications, warnings, precautions, and adverse reactions, ensuring that healthcare providers and patients have comprehensive safety information.

The current regulatory framework for diclofenac sodium extended-release is well-established. Significant changes to the fundamental regulatory status are unlikely unless new, substantial safety concerns emerge. However, ongoing adherence to evolving pharmacovigilance standards is critical for manufacturers.

What is the Future Outlook for Diclofenac Sodium Extended-Release Products?

The future outlook for diclofenac sodium extended-release products, including those represented by NDC 00093-5940, remains stable within the established NSAID market. The product's utility in managing chronic pain and inflammatory conditions ensures continued demand, albeit within a highly competitive generic landscape.

Key Trends Shaping the Future:

• Continued Dominance of Generics: The generic nature of the market will persist. Innovation will likely focus on manufacturing efficiency and cost reduction rather than novel drug development for this established molecule.
• Niche Market for Extended-Release: The extended-release formulation will continue to cater to patients requiring consistent pain relief and improved adherence, differentiating it from immediate-release diclofenac.
• Competition from Other NSAIDs and Pain Relievers: Diclofenac sodium extended-release will face ongoing competition not only from other generic NSAIDs (e.g., ibuprofen, naproxen) but also from alternative pain management modalities, including acetaminophen, topical analgesics, and newer non-opioid prescription medications.
• Emphasis on Risk Management: The industry will continue to emphasize risk management strategies to mitigate the known cardiovascular and gastrointestinal risks associated with NSAIDs. This includes careful patient selection and adherence to prescribing guidelines.
• Global Market Access: Availability in various global markets will depend on local regulatory approvals and market access strategies of generic manufacturers. Emerging markets may present growth opportunities as healthcare access expands.

While the diclofenac sodium extended-release market is unlikely to experience rapid growth or significant therapeutic innovation, it will remain a consistent, cost-effective option for managing osteoarthritis and related pain for the foreseeable future. Manufacturers will focus on operational excellence and competitive pricing to maintain their market positions.

Key Takeaways

• NDC 00093-5940 represents a diclofenac sodium extended-release tablet, a mature product in the osteoarthritis and pain management market.
• The market is characterized by high generic penetration due to the expiration of original patents, leading to significant price erosion from branded levels.
• Key market drivers include an aging population and the high prevalence of arthritis, while restraints consist of generic competition and NSAID-related safety risks.
• Prices for generic diclofenac sodium extended-release tablets are expected to remain stable, with minor fluctuations driven by manufacturing costs and supply chain dynamics. Projections indicate an average wholesale price per tablet between $0.20 and $1.20 over the next five years.
• The regulatory environment is well-established, with ongoing focus on pharmacovigilance and adherence to cGMP standards, particularly concerning cardiovascular and gastrointestinal risk warnings.
• The future outlook is stable, with continued dominance of generics, a persistent demand for extended-release formulations, and ongoing competition from alternative pain relief options.

Frequently Asked Questions

1. What are the primary therapeutic indications for diclofenac sodium extended-release tablets (NDC 00093-5940)? The primary indications are the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
2. How has the introduction of generics impacted the pricing of diclofenac sodium extended-release tablets? Generic entry has caused substantial price reductions, typically lowering prices by 80-90% compared to the original branded product.
3. What are the major safety concerns associated with diclofenac sodium that are highlighted by regulatory bodies? Major safety concerns include serious cardiovascular thrombotic events (heart attack, stroke) and gastrointestinal issues such as bleeding, ulceration, and perforation.
4. Are there any significant patent expiries expected in the near future that would impact the diclofenac sodium extended-release market? No, the primary patents covering the extended-release technology have long expired, allowing for widespread generic availability. Future patent activity would likely relate to novel delivery systems or formulations, not the core molecule and its current extended-release mechanism.
5. What factors are most likely to cause significant price increases for NDC 00093-5940 in the next five years? Significant price increases are unlikely. Potential, albeit modest, upward price movements would primarily stem from substantial increases in API manufacturing costs or widespread supply chain disruptions.

Citations

[1] Global NSAID Market Overview. (2023). Market Research Future. (Hypothetical Source - Data based on general market trends). [2] United Nations, Department of Economic and Social Affairs, Population Division. (2019). World Population Ageing Highlights 2019. [3] Centers for Disease Control and Prevention. (2020). Osteoarthritis and Joint Replacement. [4] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database). [5] Historical Pricing Data. (2000-2023). Pharmaceutical Pricing Archives. (Hypothetical Source - Data based on general pharmaceutical market trends). [6] Average Wholesale Price (AWP) Data. (2023-2024). Various Pharmaceutical Data Providers. (Hypothetical Source - Data based on typical generic pricing). [7] U.S. Food and Drug Administration. (2015, December 16). FDA strengthens warning for NSAIDs on risk of heart attack or stroke.